Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleDrug Discovery and Translational Medicine
Open Access

Danirixin: A Reversible and Selective Antagonist of the CXC Chemokine Receptor 2

Jakob Busch-Petersen, Donald C. Carpenter, Miriam Burman, James Foley, Gerald E. Hunsberger, David J. Kilian, Michael Salmon, Ruth J. Mayer, John G. Yonchuk and Ruth Tal-Singer
Journal of Pharmacology and Experimental Therapeutics August 2017, 362 (2) 338-346; DOI: https://doi.org/10.1124/jpet.117.240705
Jakob Busch-Petersen
GSK R&D, King of Prussia PA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Donald C. Carpenter
GSK R&D, King of Prussia PA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Miriam Burman
GSK R&D, King of Prussia PA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
James Foley
GSK R&D, King of Prussia PA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gerald E. Hunsberger
GSK R&D, King of Prussia PA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David J. Kilian
GSK R&D, King of Prussia PA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael Salmon
GSK R&D, King of Prussia PA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ruth J. Mayer
GSK R&D, King of Prussia PA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John G. Yonchuk
GSK R&D, King of Prussia PA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ruth Tal-Singer
GSK R&D, King of Prussia PA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading
Submit a Response to This Article
Compose eLetter

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests

Vertical Tabs

Jump to comment:

No eLetters have been published for this article.
PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 362 (2)
Journal of Pharmacology and Experimental Therapeutics
Vol. 362, Issue 2
1 Aug 2017
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Danirixin: A Reversible and Selective Antagonist of the CXC Chemokine Receptor 2
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleDrug Discovery and Translational Medicine

Danirixin: A Reversible and Selective Antagonist of CXCR2

Jakob Busch-Petersen, Donald C. Carpenter, Miriam Burman, James Foley, Gerald E. Hunsberger, David J. Kilian, Michael Salmon, Ruth J. Mayer, John G. Yonchuk and Ruth Tal-Singer
Journal of Pharmacology and Experimental Therapeutics August 1, 2017, 362 (2) 338-346; DOI: https://doi.org/10.1124/jpet.117.240705

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleDrug Discovery and Translational Medicine

Danirixin: A Reversible and Selective Antagonist of CXCR2

Jakob Busch-Petersen, Donald C. Carpenter, Miriam Burman, James Foley, Gerald E. Hunsberger, David J. Kilian, Michael Salmon, Ruth J. Mayer, John G. Yonchuk and Ruth Tal-Singer
Journal of Pharmacology and Experimental Therapeutics August 1, 2017, 362 (2) 338-346; DOI: https://doi.org/10.1124/jpet.117.240705
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Authorship Contributions
    • Footnotes
    • Abbreviations
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Glucose transport modulators and mouse behavioral testing
  • Translational PK/PD Modeling of M3258
  • Kidney protective effects of BI 685509
Show more Drug Discovery and Translational Medicine

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics